Joaquı́n Mateo
Universitat Autònoma de Barcelona · 502 works · 24,636 citations · h-index 62
Top works
- Integrative Clinical Genomics of Advanced Prostate Cancer
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- Olaparib for Metastatic Castration-Resistant Prostate Cancer
- Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
- Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
- Genomic correlates of clinical outcome in advanced prostate cancer
- A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
- Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
- Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
- Integrative Clinical Genomics of Advanced Prostate Cancer
- Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
- Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
- Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
- PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
- Delivering precision oncology to patients with cancer
- Baseline neutrophil–lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use
- Managing Nonmetastatic Castration-resistant Prostate Cancer
- An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib
- Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration
- Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer